Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H20N2O7 |
| Molecular Weight | 388.3713 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)=O
InChI
InChIKey=NCUCGYYHUFIYNU-QGZVFWFLSA-N
InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3/t17-/m1/s1
Originator
Sources: Ohno, S., O. Komatsu, K. Mizukoshi, N. Akimatsu and N. Oda, 1991, Synthesis of metabolites of MPC-1304, a new calcium antagonist, and related compounds and optical resolution of MPC-1304 and related compounds, J. Pharmacobio-Dyn. 14, s-108
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8519282
Approval Year
Sample Use Guides
oral (R)-MPC-1304 (R-aranidipine) has no hypotensive effects in conscious spontaneously hypertensive rats in doses up to 10 mg/kg
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
29935069
Created by
admin on Sat Dec 16 10:07:35 GMT 2023 , Edited by admin on Sat Dec 16 10:07:35 GMT 2023
|
PRIMARY | |||
|
148372-43-4
Created by
admin on Sat Dec 16 10:07:35 GMT 2023 , Edited by admin on Sat Dec 16 10:07:35 GMT 2023
|
PRIMARY | |||
|
4G1ZS7GQ2R
Created by
admin on Sat Dec 16 10:07:35 GMT 2023 , Edited by admin on Sat Dec 16 10:07:35 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
